1. Home
  2. SHOT vs CGTX Comparison

SHOT vs CGTX Comparison

Compare SHOT & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SHOT
  • CGTX
  • Stock Information
  • Founded
  • SHOT 2018
  • CGTX 2007
  • Country
  • SHOT United States
  • CGTX United States
  • Employees
  • SHOT N/A
  • CGTX N/A
  • Industry
  • SHOT Biotechnology: Pharmaceutical Preparations
  • CGTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SHOT Health Care
  • CGTX Health Care
  • Exchange
  • SHOT Nasdaq
  • CGTX Nasdaq
  • Market Cap
  • SHOT 31.4M
  • CGTX 30.0M
  • IPO Year
  • SHOT 2020
  • CGTX 2021
  • Fundamental
  • Price
  • SHOT $0.53
  • CGTX $0.64
  • Analyst Decision
  • SHOT
  • CGTX Strong Buy
  • Analyst Count
  • SHOT 0
  • CGTX 6
  • Target Price
  • SHOT N/A
  • CGTX $8.30
  • AVG Volume (30 Days)
  • SHOT 750.8K
  • CGTX 891.3K
  • Earning Date
  • SHOT 03-31-2025
  • CGTX 03-25-2025
  • Dividend Yield
  • SHOT N/A
  • CGTX N/A
  • EPS Growth
  • SHOT N/A
  • CGTX N/A
  • EPS
  • SHOT N/A
  • CGTX N/A
  • Revenue
  • SHOT $652,495.00
  • CGTX N/A
  • Revenue This Year
  • SHOT N/A
  • CGTX N/A
  • Revenue Next Year
  • SHOT N/A
  • CGTX N/A
  • P/E Ratio
  • SHOT N/A
  • CGTX N/A
  • Revenue Growth
  • SHOT 68.01
  • CGTX N/A
  • 52 Week Low
  • SHOT $0.45
  • CGTX $0.34
  • 52 Week High
  • SHOT $4.05
  • CGTX $2.95
  • Technical
  • Relative Strength Index (RSI)
  • SHOT 43.17
  • CGTX 43.76
  • Support Level
  • SHOT $0.45
  • CGTX $0.60
  • Resistance Level
  • SHOT $0.52
  • CGTX $0.82
  • Average True Range (ATR)
  • SHOT 0.05
  • CGTX 0.06
  • MACD
  • SHOT 0.01
  • CGTX -0.02
  • Stochastic Oscillator
  • SHOT 59.06
  • CGTX 18.56

About SHOT Safety Shot Inc.

Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Share on Social Networks: